HRP20031071A2 - Use of nk-1 receptor antagonists for the treatment of brain, spinal or nerve injury - Google Patents

Use of nk-1 receptor antagonists for the treatment of brain, spinal or nerve injury

Info

Publication number
HRP20031071A2
HRP20031071A2 HR20031071A HRP20031071A HRP20031071A2 HR P20031071 A2 HRP20031071 A2 HR P20031071A2 HR 20031071 A HR20031071 A HR 20031071A HR P20031071 A HRP20031071 A HR P20031071A HR P20031071 A2 HRP20031071 A2 HR P20031071A2
Authority
HR
Croatia
Prior art keywords
spinal
brain
treatment
receptor antagonists
nerve injury
Prior art date
Application number
HR20031071A
Other languages
English (en)
Inventor
Torsten Hoffmann
Alan John Nimmo
Andrew Sleight
Pierre Vankan
Robert Vink
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HRP20031071A2 publication Critical patent/HRP20031071A2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20031071A 2001-07-10 2003-12-22 Use of nk-1 receptor antagonists for the treatment of brain, spinal or nerve injury HRP20031071A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01116812 2001-07-10
PCT/EP2002/007323 WO2003006016A2 (fr) 2001-07-10 2002-07-03 Utilisation d'antagonistes du recepteur nk-1 pour le traitement des lesions cerebrales, medullaires ou nerveuses

Publications (1)

Publication Number Publication Date
HRP20031071A2 true HRP20031071A2 (en) 2004-06-30

Family

ID=8178001

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20031071A HRP20031071A2 (en) 2001-07-10 2003-12-22 Use of nk-1 receptor antagonists for the treatment of brain, spinal or nerve injury

Country Status (24)

Country Link
US (3) US20030083345A1 (fr)
EP (2) EP1621195A3 (fr)
JP (1) JP2004536119A (fr)
KR (1) KR100589106B1 (fr)
CN (1) CN100346789C (fr)
AR (1) AR037008A1 (fr)
AU (1) AU2002328837B2 (fr)
BR (1) BR0210893A (fr)
CA (1) CA2451566C (fr)
GT (1) GT200200143A (fr)
HK (1) HK1068266A1 (fr)
HR (1) HRP20031071A2 (fr)
HU (1) HUP0401210A3 (fr)
IL (1) IL159350A0 (fr)
MX (1) MXPA04000278A (fr)
NO (1) NO332847B1 (fr)
NZ (1) NZ530107A (fr)
PA (1) PA8549901A1 (fr)
PE (1) PE20030238A1 (fr)
PL (1) PL211246B1 (fr)
RU (1) RU2304435C2 (fr)
UY (1) UY27374A1 (fr)
WO (1) WO2003006016A2 (fr)
ZA (1) ZA200400138B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1303490T3 (da) * 2000-07-14 2008-08-25 Hoffmann La Roche N-oxider som NK1-receptorantagoniskprodugs af 4-phenyl-pyridinderivater
DK1643998T3 (da) 2003-07-03 2007-12-27 Hoffmann La Roche NK1/NK3-antagonister til behandling af skizofreni
GB0410215D0 (en) * 2004-05-07 2004-06-09 Lescroart Pol Nerve damage
MX2007000198A (es) 2004-07-06 2007-03-15 Hoffmann La Roche Proceso para la preparacion de derivados de carboxamida-piridina utilizados como intermediarios en la sintesis de antagonistas del receptor nk-1.
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
EP1856052B1 (fr) * 2005-02-22 2009-09-02 F.Hoffmann-La Roche Ag Antagonistes de nk1
EP2281556A1 (fr) 2005-02-25 2011-02-09 F. Hoffmann-La Roche AG Comprimés avec une meilleure dispersibilité de substance des médicaments
DK1863767T3 (da) * 2005-03-23 2009-05-04 Hoffmann La Roche Metabolitter til NK-I-antagonister til emesis
KR20150041174A (ko) 2005-11-08 2015-04-15 버텍스 파마슈티칼스 인코포레이티드 Ａｔｐ 결합 카세트 수송체의 헤테로사이클릭 조정제
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
DE102007018151A1 (de) * 2007-04-16 2008-10-23 Günenthal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
AU2008251504B2 (en) 2007-05-09 2013-07-18 Vertex Pharmaceuticals Incorporated Modulators of CFTR
AU2008278273A1 (en) * 2007-07-19 2009-01-22 Adelaide Research & Innovation Pty Ltd Method for reducing intracranial pressure
DK2639224T3 (en) 2007-12-07 2016-10-17 Vertex Pharma A process for the preparation of cycloalkylcarboxiamido-pyridinbenzoesyrer
EP3170818B1 (fr) 2007-12-07 2020-02-19 Vertex Pharmaceuticals Incorporated Formes solides d'acide benzoïque 3-(6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl)
WO2009108657A2 (fr) 2008-02-28 2009-09-03 Vertex Pharmaceuticals Incorporated Dérivés hétéroaryles convenant comme modulateurs du cftr
GB0808747D0 (en) * 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
HUE056525T2 (hu) 2010-04-07 2022-02-28 Vertex Pharma 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)ciklopropánkarboxamido)-3-metilpiridin-2-il)benzoesav gyógyszerészeti készítményei és azok adagolása
CA2914515C (fr) 2013-07-02 2018-12-11 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Procede de prevention et/ou de traitement de l'encephalopathie traumatique chronique-i
EP3016657B1 (fr) * 2013-07-02 2019-06-26 Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) Procédé pour la prévention et/ou le traitement de l'encéphalopathie traumatique chronique-ii
US20160129007A1 (en) * 2013-07-02 2016-05-12 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Method for Preventing and/or Treating Chronic Traumatic Encephalopathy - IV
WO2015068744A1 (fr) 2013-11-08 2015-05-14 キッセイ薬品工業株式会社 Dérivé de carboxyméthylpipéridine
US10231932B2 (en) 2013-11-12 2019-03-19 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
DK3221692T3 (da) 2014-11-18 2021-08-23 Vertex Pharma Fremgangsmåde til udførsel af tests med høj kapacitet ved hjælp af højtryksvæskekromatografi
CA3089662A1 (fr) * 2018-02-02 2019-08-08 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Formulations parenterales et leurs utilisations
KR101970099B1 (ko) * 2018-02-07 2019-04-17 한국과학기술연구원 척수 손상의 예방 및 치료용 조성물
KR102005019B1 (ko) * 2018-04-04 2019-07-31 한국과학기술연구원 뇌졸중의 예방 및 치료용 조성물
EP4017589A4 (fr) * 2019-08-23 2023-09-20 Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) Méthodes thérapeutiques et utilisations associées

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745123A (en) * 1986-02-18 1988-05-17 Warner-Lambert Company Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
IL111002A (en) * 1993-09-22 1998-09-24 Glaxo Group Ltd History of piperidine, their preparation and the pharmaceutical preparations containing them
US6175013B1 (en) * 1994-06-10 2001-01-16 Eli Lilly And Company Imidazolinyl tachykinin receptor antagonists
US5607947A (en) * 1995-02-21 1997-03-04 Eli Lilly And Company Pyrrolidinyl tachykinin receptor antagonists
IL116249A (en) * 1994-12-12 2003-07-06 Pfizer Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
TW382017B (en) * 1995-12-27 2000-02-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives
US6214846B1 (en) * 1997-06-27 2001-04-10 Merck Sharp & Dohme Limited Substituted 3-(benzylamino)piperidine derivatives and their use as therapeutic agents
US5972938A (en) * 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
DK1394150T3 (da) * 1999-02-24 2011-03-21 Hoffmann La Roche 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
BR0008494A (pt) * 1999-02-24 2002-02-05 Hoffmann La Roche Derivados de 3-fenilpiridina e seu uso como antagonista do receptor de nk-1
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
ES2208205T3 (es) * 1999-11-29 2004-06-16 F. Hoffmann-La Roche Ag 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-otolil-piridin-3-il)-isobutiramida.
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
AUPQ514600A0 (en) * 2000-01-18 2000-02-10 James Cook University Brain injury treatment

Also Published As

Publication number Publication date
KR20040029362A (ko) 2004-04-06
WO2003006016A3 (fr) 2003-07-31
EP1406618A2 (fr) 2004-04-14
AU2002328837B2 (en) 2005-05-05
CN100346789C (zh) 2007-11-07
NO20040057L (no) 2004-01-07
CA2451566A1 (fr) 2003-01-23
US20110053954A1 (en) 2011-03-03
GT200200143A (es) 2002-11-11
WO2003006016A2 (fr) 2003-01-23
PL369535A1 (en) 2005-05-02
RU2004102397A (ru) 2005-04-20
RU2304435C2 (ru) 2007-08-20
HUP0401210A3 (en) 2011-07-28
PE20030238A1 (es) 2003-03-19
UY27374A1 (es) 2003-03-31
NZ530107A (en) 2006-01-27
PL211246B1 (pl) 2012-04-30
CA2451566C (fr) 2013-09-10
KR100589106B1 (ko) 2006-06-14
BR0210893A (pt) 2004-06-22
HK1068266A1 (en) 2005-04-29
ZA200400138B (en) 2005-06-29
US20060247240A1 (en) 2006-11-02
US20030083345A1 (en) 2003-05-01
AR037008A1 (es) 2004-10-20
HUP0401210A2 (hu) 2004-10-28
EP1621195A2 (fr) 2006-02-01
JP2004536119A (ja) 2004-12-02
MXPA04000278A (es) 2004-05-04
NO332847B1 (no) 2013-01-21
EP1621195A3 (fr) 2010-01-06
IL159350A0 (en) 2004-06-01
CN1523988A (zh) 2004-08-25
PA8549901A1 (es) 2003-01-24

Similar Documents

Publication Publication Date Title
HRP20031071A2 (en) Use of nk-1 receptor antagonists for the treatment of brain, spinal or nerve injury
HK1054872A1 (en) Brain, spinal and nerve injury treatment
AP2004002982A0 (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain.
EP1420854A4 (fr) Traitement de troubles neuropsychiatriques par stimulation nerveuse a proximite du diaphragme
EP1434801A4 (fr) Traitement pour des troubles du systeme nerveux central
PL363907A1 (en) Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain.
AU2003249983A8 (en) Piperidines useful for the treatment of central nervous system disorders
IL176581A0 (en) Immunomodulatory compounds for the treatment of central nervous system disorders
HK1152243A1 (en) Vegf for use in the treatment of central nervous system disorders vegf
IL160483A0 (en) Treatment of disorders by unidirectional nerve stimulation
PL372425A1 (en) Dihydrobenzodiazepin-2-one-derivatives for the treatment of neurological disorders
IL158631A0 (en) 4-(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
AU2002356525A1 (en) Substituted amines for the treatment of neurological disorders
PL368556A1 (en) Methods for treating or preventing skin disorders using cd2-binding agents
ZA200402514B (en) 4[Piperidin-4-yliden-(3-carbamoylphenyl)methyl]benzamide derivatives and their use for the treatment of pain, spinal injuries or gastrointestinal disorders.
IL157145A0 (en) Use of dc23 antagonists for the treatment of neoplastic disorders
AU2003290059A8 (en) Use of cd137 antagonists for the treatment of tumors
IL162475A0 (en) Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
IL162053A0 (en) Method for the treatment of bone disorders
AU2003245995A8 (en) Use of gaba-c receptor antagonists for the treatment of myopia
IL218891A0 (en) Apparatus for treatment of disorders by unidirectional nerve stimulation
PL374077A1 (en) Use of 5-ht2 receptor antagonists for the treatment of sleep disorders
GB0317241D0 (en) Therapeutic agents for the treatment of bone disorders
GB0324283D0 (en) Therapeutic agents for the treatment of bone disorders
GB0305343D0 (en) Therapeutic agents for the treatment of bone disorders

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20070628

Year of fee payment: 6

OBST Application withdrawn